BEAM
Price
$20.75
Change
+$0.30 (+1.47%)
Updated
Jul 18 closing price
Capitalization
2.09B
22 days until earnings call
GYRE
Price
$7.22
Change
-$0.17 (-2.30%)
Updated
Jul 18 closing price
Capitalization
653.63M
29 days until earnings call
Interact to see
Advertisement

BEAM vs GYRE

Header iconBEAM vs GYRE Comparison
Open Charts BEAM vs GYREBanner chart's image
Beam Therapeutics
Price$20.75
Change+$0.30 (+1.47%)
Volume$2.18M
Capitalization2.09B
Gyre Therapeutics
Price$7.22
Change-$0.17 (-2.30%)
Volume$52.96K
Capitalization653.63M
BEAM vs GYRE Comparison Chart in %
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. GYRE commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and GYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (BEAM: $20.75 vs. GYRE: $7.22)
Brand notoriety: BEAM and GYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 109% vs. GYRE: 20%
Market capitalization -- BEAM: $2.09B vs. GYRE: $653.63M
BEAM [@Biotechnology] is valued at $2.09B. GYRE’s [@Biotechnology] market capitalization is $653.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileGYRE’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • GYRE’s FA Score: 1 green, 4 red.
According to our system of comparison, BEAM is a better buy in the long-term than GYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 6 TA indicator(s) are bullish while GYRE’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 6 bullish, 3 bearish.
  • GYRE’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than GYRE.

Price Growth

BEAM (@Biotechnology) experienced а -1.94% price change this week, while GYRE (@Biotechnology) price change was -3.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

BEAM is expected to report earnings on Aug 12, 2025.

GYRE is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.09B) has a higher market cap than GYRE($654M). BEAM YTD gains are higher at: -16.331 vs. GYRE (-40.331). GYRE has higher annual earnings (EBITDA): 12.1M vs. BEAM (-399.03M). BEAM has more cash in the bank: 1.22B vs. GYRE (29.9M). GYRE has less debt than BEAM: GYRE (1.59M) vs BEAM (158M). GYRE has higher revenues than BEAM: GYRE (101M) vs BEAM (63.6M).
BEAMGYREBEAM / GYRE
Capitalization2.09B654M319%
EBITDA-399.03M12.1M-3,298%
Gain YTD-16.331-40.33140%
P/E RatioN/A360.50-
Revenue63.6M101M63%
Total Cash1.22B29.9M4,080%
Total Debt158M1.59M9,968%
FUNDAMENTALS RATINGS
GYRE: Fundamental Ratings
GYRE
OUTLOOK RATING
1..100
73
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
94
SMR RATING
1..100
63
PRICE GROWTH RATING
1..100
90
P/E GROWTH RATING
1..100
8
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMGYRE
RSI
ODDS (%)
Bearish Trend 4 days ago
83%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
77%
Momentum
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
83%
MACD
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
86%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 19 days ago
81%
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
75%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LEGAX75.910.17
+0.22%
Columbia Large Cap Growth A
MAAUX2.35N/A
N/A
Morgan Stanley Inst Dynamic Value A
REQTX46.38-0.04
-0.09%
Russell Sustnbl Aware Eq S
CFWIX29.84-0.04
-0.13%
Calvert Global Water I
GABIX48.79-0.15
-0.31%
Gabelli Asset I

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+1.47%
CRSP - BEAM
70%
Closely correlated
+18.22%
NTLA - BEAM
65%
Loosely correlated
+1.94%
RXRX - BEAM
64%
Loosely correlated
+5.80%
DNLI - BEAM
63%
Loosely correlated
-3.65%
SYRE - BEAM
59%
Loosely correlated
-3.55%
More

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been closely correlated with SPHDF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if GYRE jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-2.30%
SPHDF - GYRE
82%
Closely correlated
N/A
BEAM - GYRE
42%
Loosely correlated
+1.47%
SPRC - GYRE
38%
Loosely correlated
-6.22%
AURA - GYRE
38%
Loosely correlated
-5.76%
CRBU - GYRE
38%
Loosely correlated
+12.02%
More